about
Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectivesDecision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.Qualitative modification and development of patient- and caregiver-reported outcome measures for iron chelation therapy.Hepcidin levels in Diamond-Blackfan anemia reflect erythropoietic activity and transfusion dependencyAdvances in iron chelation therapy: transitioning to a new oral formulation.Bone marrow cell transcripts from Fanconi anaemia patients reveal in vivo alterations in mitochondrial, redox and DNA repair pathways.Blood transfusion, serum ferritin, and iron in hemodialysis patients in AfricaRole of the clathrin adaptor PICALM in normal hematopoiesis and polycythemia vera pathophysiology.Polymeric nanocarriers for the treatment of systemic iron overload.Secondary haemochromatosis in a haemodialysis patient.Quality of life, clinical effectiveness, and satisfaction in patients with beta thalassemia major and sickle cell anemia receiving deferasirox chelation therapy.Evaluation of Iron Deposition in the Adrenal Glands of β Thalassemia Major Patients Using 3-Tesla MRI.The ICET-A Recommendations for the Diagnosis and Management of Disturbances of Glucose Homeostasis in Thalassemia Major Patients.Restoring the impaired cardiac calcium homeostasis and cardiac function in iron overload rats by the combined deferiprone and N-acetyl cysteine.Clinical outcomes of transfusion-associated iron overload in patients with refractory chronic anemia.Iron overload correlates with serum liver fibrotic markers and liver dysfunction: Potential new methods to predict iron overload-related liver fibrosis in thalassemia patientsIron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions.Deferasirox in a refractory anemia after other treatment options: case report and literature review.Ineffective erythropoiesis and regulation of iron status in iron loading anaemias.Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.The role of cardiac MRI in cardio-oncology.Iron chelation therapy of transfusion-dependent β-thalassemia during pregnancy in the era of novel drugs: is deferasirox toxic?Morbidities in non-transfusion-dependent thalassemia.Siderophores as molecular tools in medical and environmental applications.The questioning for routine monthly monitoring of proteinuria in patients with β-thalassemia on deferasirox chelation.How we manage iron overload in sickle cell patients.Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis.Quantitative R2* MRI of the liver with rician noise models for evaluation of hepatic iron overload: Simulation, phantom, and early clinical experience.Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients.Efficacy and Safety of Deferasirox in Pediatric Patients of Thalassemia at a Tertiary Care Teaching HospitalIron Overload and Platelet Function Defects: Possible Correlation.Retrospective comparison of gradient recalled echo R2* and spin-echo R2 magnetic resonance analysis methods for estimating liver iron content in children and adolescents.Co-Administration of Silymarin and Deferoxamine against Kidney, Liver and Heart Iron Deposition in Male Iron Overload Rat Model.Deferasirox for transfusion-dependent patients with myelodysplastic syndromes: safety, efficacy, and beyond (GIMEMA MDS0306 Trial).Iron overload-related heart failure in a patient with transfusion-dependent myelodysplastic syndrome reversed by intensive combined chelation therapy.Evolution of iron burden in acquired aplastic anemia: a cohort study of more than 3-year follow-up.Analogues of desferrioxamine B designed to attenuate iron-mediated neurodegeneration: synthesis, characterisation and activity in the MPTP-mouse model of Parkinson's disease.Safety and pharmacokinetics of the oral iron chelator SP-420 in β-thalassemia.MRI assessment of pituitary iron accumulation by using pituitary-R2 in β-thalassemia patients.Evolution of iron overload in patients with low-risk myelodysplastic syndrome: iron chelation therapy and organ complications.
P2860
Q26740347-752604E7-F625-413F-AB21-9B7EE31F3490Q30240190-7E9E07EB-3899-4406-B95E-68A29B017400Q33827300-86CBB9C5-F9BD-446A-8231-96DBD0ADDB24Q33828609-0264A1C5-1563-4F93-AE08-2E6F960F3957Q33879123-D544A8D3-A2A7-4DF2-A861-EF68FFB4D380Q34707383-12CE7545-EC05-4448-A528-CB2DA7B2050AQ35012284-03D4A934-E900-4542-AE1A-7F352354987CQ35236037-B9B105CA-C051-411E-BDCD-301A8D176A33Q35673632-3A97E749-81F8-4CB0-B76E-77F81DA6F139Q35905053-AE54A243-3BED-4E3D-94F7-E80C782B0F6EQ36719941-7EBFE5C4-DD75-4ACF-94D0-FFA0FC55EDBEQ37410866-1DDFD4DF-30FC-4B83-94BD-01E01F59E0DCQ37417551-4CB43F5B-9F09-4E74-9EFE-422D6F25A322Q37695691-D033DB83-BB6A-4127-A5F9-B5B06DA5E28EQ37729737-61609B3B-F626-4F69-90F8-35730D534627Q37741820-5E1D2FB5-6FE6-4972-94BE-BCDA0F244740Q38540491-C679E79B-1885-4053-A4FE-F73044425519Q38549248-08202A9F-F75F-4CF5-88B8-08A5E6B9BE86Q38613789-18951409-B064-463C-8475-58104A3C0D50Q38650293-E696E420-E523-4930-BAB0-705BDD49C559Q38668133-2D0EA608-742E-4499-B4FA-A6F76706A889Q38727988-89DC9409-ECF4-478A-A044-D59DD1FACBDDQ38836177-927423B5-7B9C-45DF-863E-93DBF95F89E3Q38919129-F887B9E4-4BA8-4E70-81B8-D19BCC144312Q38997520-2E776EE4-F961-4F8D-A9CF-182A5844304AQ39179372-D2F02089-55F3-4FE3-A715-A1454B8A40B9Q40892218-20306885-AB8F-4F99-A661-496E29212E98Q40915707-58041F29-DA55-42D0-9477-58B4706368A6Q41562000-E7972EB3-BD2E-46E6-91DE-415F04B37873Q41601748-446A4E3E-C3B0-40A9-89FC-40FD91B6804CQ41605854-BB397F7E-ABC4-4228-B9E0-9C032A27B29BQ41718690-4CB6661B-EDCB-40A3-9C9E-75477BB8C0D1Q41808673-87813B6E-4F9B-4231-8B23-2346D41A9E6BQ42645802-89A01B83-2C30-4765-87BB-8C0E65E74A8CQ43180054-83E01122-435C-484B-977B-D3402A4C8ADAQ43810008-47165716-1D10-4054-9C4E-A019147774A1Q46372704-41C23B70-848B-4ADF-BE33-6B96CACA440FQ48306161-8E9250D9-5595-4789-BF89-2911544B725DQ50204951-CFDE6515-DC64-446F-A09D-D1271D3E7592Q50455137-A9033B8E-44E2-492A-9B09-3BEA4C91E1FA
P2860
description
im August 2012 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 23 August 2012
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в серпні 2012
@uk
name
How I treat transfusional iron overload
@en
How I treat transfusional iron overload
@nl
type
label
How I treat transfusional iron overload
@en
How I treat transfusional iron overload
@nl
prefLabel
How I treat transfusional iron overload
@en
How I treat transfusional iron overload
@nl
P1433
P1476
How I treat transfusional iron overload
@en
P2093
A Victor Hoffbrand
P304
P356
10.1182/BLOOD-2012-05-370098
P407
P577
2012-08-23T00:00:00Z